Efficacy and Safety of Benralizumab in Patients With Non-cystic Fibrosis Bronchiectasis (MAHALE)
A Multicentre, Randomised, Double-blind, Parallel-group, Placebo-controlled, 52 Week, Phase III Study With an Open-label Extension to Evaluate the Efficacy and Safety of Benralizumab in Patients With Non-Cystic Fibrosis Bronchiectasis (MAHALE)
Sponsor: AstraZeneca
Terminated
Due to the decision to stop recruitment early, enrolment into the MAHALE trial was terminated in August 2022; 139 patients were screened and 100 randomised to IP.
Listed as NCT05006573, this PHASE3 trial focuses on Non-cystic Fibrosis Bronchiectasis and remains terminated or withdrawn. Sponsored by AstraZeneca, it has been updated 23 times since 2021, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
23 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE3
-
Aug 2025 — Sep 2025 [monthly]
Terminated PHASE3
-
Apr 2025 — Aug 2025 [monthly]
Terminated PHASE3
Status: Completed → Terminated
-
Sep 2024 — Apr 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
▶ Show 18 earlier versions
-
Jun 2024 — Jul 2024 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Feb 2024 — Jun 2024 [monthly]
Active Not Recruiting PHASE3
-
Nov 2023 — Feb 2024 [monthly]
Active Not Recruiting PHASE3
-
Sep 2023 — Nov 2023 [monthly]
Active Not Recruiting PHASE3
-
Apr 2023 — Sep 2023 [monthly]
Active Not Recruiting PHASE3
-
Jan 2023 — Apr 2023 [monthly]
Active Not Recruiting PHASE3
-
Sep 2022 — Jan 2023 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Jul 2022 — Sep 2022 [monthly]
Recruiting PHASE3
-
Jun 2022 — Jul 2022 [monthly]
Recruiting PHASE3
-
May 2022 — Jun 2022 [monthly]
Recruiting PHASE3
-
Apr 2022 — May 2022 [monthly]
Recruiting PHASE3
-
Mar 2022 — Apr 2022 [monthly]
Recruiting PHASE3
-
Feb 2022 — Mar 2022 [monthly]
Recruiting PHASE3
-
Jan 2022 — Feb 2022 [monthly]
Recruiting PHASE3
-
Dec 2021 — Jan 2022 [monthly]
Recruiting PHASE3
-
Nov 2021 — Dec 2021 [monthly]
Recruiting PHASE3
-
Oct 2021 — Nov 2021 [monthly]
Recruiting PHASE3
-
Sep 2021 — Oct 2021 [monthly]
Recruiting PHASE3
First recorded
Jul 2021
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- AstraZeneca
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Aalborg, Denmark , Ajax, Canada , Barcelona, Spain , Birmingham, United States , Burlington, Canada , Bydgoszcz, Poland , Coimbatore, India , El Paso, United States , Essen, Germany , Florida, Argentina and 35 more locations